MyCare - Patients: View your medical records securely online here.
Log in Learn More

A Multicenter, Double-blind, Randomized, Active-controlled, Study (ASPIRE) to Evaluate the Long-term Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole in Patients with Schizophrenia

Description: For patients with schizophrenia. All participants receive active medication in the double-blind study (247). Once randomized, they are eligible to participate in an open label study (248) of the Abilify long-acting depot for up to two years or when the medication is approved by the FDA.
IRB Number: 1112B
Status: Enrolling
Start Date: August 01, 2008
Principal Name: Kashinath Patil, MD
Contact Name: Terrance Bellnier, RPh, MPA, FASCP
Phone: 585-739-5880